Marker Therapeutics Inc (MRKR) is a clinical stage immuno-oncology company, which focuses on the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications.
With an asset/liability ratio of more than 2x, MRKR’s balance sheet seems very solid. MRKR reports $21 million in cash and cash equivalents. As for me, I think that the company has a good amount of cash to conduct additional R&D and increase its marketing efforts.
MRKR’s short term debt is less significant than the cash in hand. Thus, the company will not worry about any liquidity risk. That’s not all, I believe that MRKR is cheap. Notice that the cash per share is equal to $0.4, and the stock price is $1.8. Finally, MRKR’s debt to equity ratio is below 2x. In summary, the company does not have a significant amount of debt.
The company’s R&D expenses were equal to $5.983476 million, with selling and marketing expenses of $0.2525 million. With this in mind, either you buy shares or not, MRKR is a company to be followed carefully. When the company commences to sell its product candidates, or they are approved by the FDA, the stock price will run.
Recent News: Investors Gave More Cash To The Company
Today, the company announced the results of a new offering in which the company receives $56.5 million. This is great news. In my opinion, market participants will be buying shares:
The gross proceeds to Marker from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $56.5 million.
Disclosure: I don’t own shares, but I may buy soon.
For more stock picks sign up below: